BIOMAT Database Logo BIOMAT Database Logo

[Hereditary angioneurotic oedema]. 1971

K Ohela, and A Taipale, and O Wager, and J A Räsänen

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007705 Kinins A generic term used to describe a group of polypeptides with related chemical structures and pharmacological properties that are widely distributed in nature. These peptides are AUTACOIDS that act locally to produce pain, vasodilatation, increased vascular permeability, and the synthesis of prostaglandins. Thus, they comprise a subset of the large number of mediators that contribute to the inflammatory response. (From Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th ed, p588) Kinin
D008297 Male Males
D008777 Methyltestosterone A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL). 17 beta Methyltestosterone,17 beta-Hydroxy-17-methyl-4-androsten-3-one,17 beta-Methyltestosterone,17-Epimethyltestosterone,17-alpha-Methyltestosterone,17alpha-Methyl-Testosterone,17alpha-Methyltestosterone,17beta-Hydroxy-17-methyl-4-androsten-3-one,17beta-Methyltestosterone,Android (Methyltestoterone),Android-10,Android-25,Android-5,Mesteron,Mesterone,Metandren,Methitest,Oreton,Testoviron,Testred,Virilon,17 Epimethyltestosterone,17 alpha Methyltestosterone,17 beta Hydroxy 17 methyl 4 androsten 3 one,17alpha Methyl Testosterone,17alpha Methyltestosterone,17beta Hydroxy 17 methyl 4 androsten 3 one,17beta Methyltestosterone,Android 10,Android 25,Android 5
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004950 Esterases Any member of the class of enzymes that catalyze the cleavage of an ester bond and result in the addition of water to the resulting molecules. Esterase

Related Publications

K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
September 1980, The Journal of laryngology and otology,
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
July 1975, Klinische Wochenschrift,
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
February 1979, Anaesthesia,
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
October 1973, The New Zealand medical journal,
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
May 1973, Lancet (London, England),
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
June 1973, Lancet (London, England),
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
September 1973, Lancet (London, England),
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
August 1973, Lancet (London, England),
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
July 1973, Lancet (London, England),
K Ohela, and A Taipale, and O Wager, and J A Räsänen
Hereditary angioneurotic oedema.
June 1973, Lancet (London, England),
Copied contents to your clipboard!